Regional variation in surgery for pancreatic cancer in Denmark 2011-2015

Kasper Wennervaldt, Anne Mette Kejs, Henriette Lipczak, Paul Bartels, Michael Borre, Claus Wilki Fristrup, Henrik Kehlet

    Research output: Contribution to journalJournal articleResearchpeer-review

    16 Downloads (Pure)

    Abstract

    INTRODUCTION: Surgical treatment for pancreatic cancer carries a high risk of both morbidity and mortality. Even so, it remains the best curative treatment option. In Denmark, pancreatic surgery has been extensively centralised since the millennium, but the, effect of this centralisation on patient outcome has not been evaluated. This study describes regional variation within pancreatic surgery on a malignant indication, focusing on production volume, length of stay, readmission rates and mortality. METHODS: This is a retrospective cohort study of all patients with pancreatic cancer who underwent surgical treatment in Denmark from 2011 to 2015. We obtained data from the Danish National Patient. Registry and the National Pathology Data Bank on length of stay, transfers, mortality (both short and long term), age, co-morbidity, and disease stage. RESULTS: Four hospital units performed a total of 691 surgical procedures (476 pancreaticoduodenectomies) in the study period. Production volume varied considerably across units with two units accounting for nearly 80% of surgery performed. Data revealed variation on rates of transfers and readmissions as well as disease stage and mortality (both short and long term). CONCLUSIONS: DATA suggest that mortality is linked to production volume as well as disease stage, but the small data quantity impedes rigorous statistical analysis. Further studies on the observed associations are required.
    Original languageEnglish
    Article numberA5503
    JournalDanish Medical Journal
    Volume65
    Issue number9
    Number of pages5
    ISSN2245-1919
    Publication statusPublished - 1. Sep 2018

    Fingerprint Dive into the research topics of 'Regional variation in surgery for pancreatic cancer in Denmark 2011-2015'. Together they form a unique fingerprint.

    Cite this